Pay in 4 interest-free payments of $6.10 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
One article found an increased incidence of aspiration pneumonia among GLP-1 users compared to non-users reporting a hazard ratio of 1.33 (95%CI 1.021.74, p = 0.036) (Australian Diabetes Society, National Association of Clinical Obesity Services, Gastroenterological Society of Australia, and Australian and New Zealand College of Anaesthetists n.d.)
Meta-analyses show modest but statistically significant weight loss, primarily in overweight or obese adults and people with low baseline carnitine levels (vegans/vegetarians, older adults)
This offer operates outside any third-party insurance and is not valid for prescriptions covered by government insurance programs, such as Medicare and Medicaid, or similar federal or state programs
Available in multiple vial strengths (600 mg and 1500 mg) to suit diverse research models
The SURPASS-SEMA trial (NCT05583292) compared tirzepatide directly to semaglutide 1.0 mg in type 2 diabetes, showing tirzepatide 10 mg and 15 mg produced superior HbA1c and weight reductions [11]
